| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Laboratory Medicine, Divisions of Molecular Medicine [K. H., A. J., S. B., S. P.] and Pathology [Å. K., E. N., G. L.], Lund University, S-20502 Malmö, Sweden
| ABSTRACT |
|---|
|
|
|---|
protein levels, down-regulated estrogen receptor-
, and increased expression of the epithelial breast stem cell marker cytokeratin 19; lose their polarization; and acquire an increased nucleus/cytoplasm ratio, hallmarks of poor architectural and cellular differentiation. The hypoxia-induced changes were confirmed in cultured breast cancer cells. We propose that hypoxia-induced dedifferentiation is a mechanism that promotes tumor progression in breast cancer. | Introduction |
|---|
|
|
|---|
3
and HIF-2
(4, 5, 6)
. Occurrence of hypoxia within a given tumor form is generally associated with a worse prognosis. This phenomenon is believed to be caused by a higher mutation rate and higher metastatic potential in hypoxic tumors, as well as a diminished response to radiation treatment and chemotherapy (7, 8, 9)
. We recently demonstrated that human neuroblastoma cells grown under hypoxic conditions lose their neuronal characteristics and develop a neural crest-like phenotype, changes that also occurred in vivo in necrotic areas of xenografted neuroblastoma tumors (10)
. In neuroblastoma, there is a well-established correlation between low expression levels of neuronal differentiation marker genes and highly malignant tumor behavior (11)
. On the basis of these two sets of observations, we hypothesized that hypoxia-induced dedifferentiation in neuroblastoma promotes a tumor phenotype with aggressive behavior (10)
. In this report we asked whether hypoxia-induced dedifferentiation is a general phenomenon that occurs in solid tumors other than neuroblastoma. As a first model we chose DCIS, a breast tumor characterized by well-defined tumor lesions with distinct areas of necrosis, lack of vascularization within the lesions, and focal stabilization of HIF-1
in the cells surrounding the central necrosis (Ref. 12
; Fig. 1, A and B
protein expression. Parallel to these morphological changes, there was a down-regulation of ER
and an up-regulation of CK19, an epithelial breast stem cell marker (13)
. These changes in gene expression were also seen in hypoxia-treated breast cancer cell lines. We conclude that within the hypoxic region of DCIS, tumor cells acquire a less mature, dedifferentiated phenotype.
|
| Materials and Methods |
|---|
|
|
|---|
Histology and Immunohistochemistry.
H&E-stained sections were used for morphological grading of the DCIS lesions. The following monoclonal antibodies were used: anti-ER
(dilution, 1:200; DAKO A/S, Glostrup, Denmark), anti-CK19 (1:50; DAKO), Ki-67 (1:200; DAKO), and anti-HIF-1
(1:400; Abcam, Cambridge, United Kingdom). ER
, CK19, and Ki-67 immunohistochemistry was performed in a DAKO TechMate 500 after antigen retrieval by microwave treatment in citrate buffer (pH 6). HIF-1
immunohistochemistry was performed manually after antigen retrieval with DAKO Target Retrieval Solution. Immunoreactivity was visualized using the DAKO Catalyzed Signal Amplification System. All sections were counterstained with hematoxylin, and negative controls were obtained by omitting the primary antibody.
DNA fragmentation as a sign of apoptosis was visualized in tissue sections using TUNEL labeling according to the ApoAlert DNA Fragmentation Assay Kit User Manual (BD Biosciences Clontech, Palo Alto, CA). For cell culture arrays, cytoplasmic staining intensity of CK19 was graded as 0 < 1 < 2 < 3. For the nuclear antigens ER
and Ki-67, nuclear staining was scored as positive. To manually count cells, two fields were randomly chosen for each immunohistochemical staining and photographed at x20 magnification. All cells within a field were counted (300400 cells) and evaluated twice. Average intensity score was calculated for the controls and the hypoxic cells, and the relative change in staining intensity was shown diagrammatically. Statistical analyses were performed using the Mann-Whitney test.
To calculate the N/C ratio, the most symmetrical DCIS lesion with a central necrosis was chosen in each of the 19 tumor sections and photographed at x40 magnification. The cytoplasmic and nuclear areas of cells from the basal membrane to the central necrosis were measured in two different places within each DCIS lesion, using the Image-Pro Plus 4.0 image analyzing software. The number of cell layers varied between 4 and 10 as indicated in Fig. 1D
. The average N/C ratio was then calculated for each tumor. Statistical analyses were performed using the Mann-Whitney test. Two tumors were excluded: one attributable to lack of suitable lesions and one because irregular cell morphology made it impossible to determine the N/C ratio.
Western Blot and Flow Cytometry Analyses.
Western blot analyses were performed as described previously (10)
with the same antibodies used in the immunohistochemical studies. The Western blot analyses were performed six times with anti-ER and four times with anti-CK19 antibodies, and the same results were obtained. Flow cytometry analyses were performed five times as described previously (14)
.
| Results and Discussion |
|---|
|
|
|---|
expression within the DCIS lesions. Immunohistochemistry revealed a gradient in HIF-1
staining, with the strongest signal in the cell layers surrounding the central necrosis (Fig. 1, A and B)
signal was found close to areas of necrosis suggested that this staining defines a hypoxic zone of tumor cells. Although most of the studied DCISs were poorly differentiated (nuclear grade III), we observed DCIS lesions with a higher differentiation state in 7 of 19 cases, i.e., there was cellular polarization with radial orientation of the apex of the cells toward an intercellular lumen. Interestingly, these features were lost with growing proximity to the central necrosis (Fig. 1C)
We next tested whether the changes in cell morphology in the hypoxic zone were accompanied by alterations in the expression of genes normally associated with the differentiation status of breast tumors. The ER expression in breast cancer cells correlates positively to the degree of cellular differentiation (16)
: cancers with high levels of ER have a better prognosis than those with low levels or no receptor expression. Of the 19 tested tumors, 8 stained positive for ER
, with the staining confined to the nuclei of the tumor cells (Fig. 2, A and B)
. Although staining intensity could vary between DCIS lesions, all but the innermost cell layers were ER
positive, i.e., the 26 cell layers in closest proximity to the necrosis were ER
negative (Fig. 2, A and B)
. The changes in nuclear morphology and ER
expression suggested that cells closer to the necrotic area had acquired a more malignant, less differentiated phenotype. We therefore tested CK19, a marker of early mammary gland development (17
, 18)
expressed in stem cells in the adult breast (13
, 17 , 18)
whose level of expression is proportional to tumor grade in invasive and in situ breast carcinoma (19
, 20)
. We found CK19 expression throughout the lesions, but the staining intensity was greatly enhanced within the hypoxic zone (Fig. 2, C and D)
. Staining for myoepithelial markers CK14 and vimentin showed no hypoxic zone-related up-regulation of expression in the DCIS (data not shown). To test whether the changes in ER
and CK19 expression could be secondary to hypoxia-induced cell death, we stained the tumor lesions for fragmented DNA, using the TUNEL method. As shown in Fig. 2G
, there were few apoptotic cells, and no apparent gradient of dying cells toward the necrotic center was seen.
|
|
and CK19 expression patterns under defined hypoxic conditions. In our recent study of neuroblastoma cells and their response to hypoxia, we found that the cells remained vital for at least 3 days at 1% oxygen and that these conditions induced dedifferentiation (10)
. We therefore applied these growth conditions to three ER
-positive breast cancer cell lines, MCF7, CAMA, and T47D, derived from mammary ductal carcinoma. Flow cytometry analysis revealed that the hypoxic cultures contained a smaller fraction of dead cells than their normoxic counterparts (Fig. 3C)
, CK19, and Ki-67 was analyzed under those conditions with use of cell microarrays and immunocytochemistry (Fig. 3A)
, up-regulation of CK19, and a decrease in Ki-67 expression in all three cell lines studied (Fig. 3A)
was most pronounced in T47D, whereas the increase in CK19 expression was highest in CAMA cells, suggesting that cells differ in their sensitivity to low oxygen pressure. To further verify the changes in gene expression, we analyzed cell extracts of normoxic and hypoxic breast cancer cell lines by Western blotting, which confirmed the hypoxia-induced down-regulation of ER
expression as well as the quantitative differences noted in the cell culture arrays (Fig. 3B)
Having chosen DCIS as a model for focal hypoxia in solid tumors, we set the presence of a central necrosis within the DCIS lesions as the main criterion for selection of tumor specimens for this study. DCISs with extensive necrosis are generally poorly differentiated (15)
. Nevertheless, the N/C ratios increased with hypoxia, and in lesions where the tumor cells had retained some architectural differentiation, these features were lost toward the central necrosis. In none of the investigated tumors did the hypoxic cells appear more differentiated than tumor cells at the basal membrane, and because the expression of ER
decreased with hypoxia, these observations suggested that hypoxia gives rise to a more immature phenotype. This conclusion is in accordance with a recent study showing that HIF-1
expression correlates with a high grade of malignancy in DCIS as well as in invasive breast cancer (12)
.
Our observation that hypoxia induces dedifferentiation and HIF-1
expression in DCIS cells suggests that it is dedifferentiation that drives the hypoxia-associated promotion of the aggressive phenotype in breast cancer, neuroblastoma, and possibly other cancer forms. Mammary epithelial differentiation involves stepwise acquisition of a CK expression pattern specific for the luminal and the myoepithelial cells, respectively. During the early weeks of gestation, the two cell types develop from CK19-positive cells (17)
. CK19, a marker of the luminal phenotype in the adult gland, is therefore also one of the earliest markers of mammary gland development, and mammary multipotent progenitor cells in the adult organ are found among the CK19-positive luminal cells (13)
. Thus, the up-regulation of CK19 and down-regulation of ER
, together with the loss of morphological differentiation features in the hypoxic zone of DCIS, strongly suggest that hypoxia promotes the development of immature tumor cells. The hypoxia-induced down-regulation of ER
expression in DCIS (Fig. 2, A and B)
and in invasive mammary carcinoma4
has potential clinical relevance and suggests a reason that some ER
-positive tumors are/become resistant to antiestrogen treatment. This in turn suggests that increasing oxygen tension in these tumors might enhance the therapeutic effect of antiestrogens. In addition, progression to infiltrative carcinoma is associated with suppression of myoepithelial cell-specific intermediate filament expression and up-regulation of CK19 (19
, 20)
.
DCIS, if left untreated, becomes invasive, and because hypoxic DCIS cells acquire an immature, CK19-positive phenotype, increased invasiveness could be another consequence of the development of hypoxic regions in breast cancer. It remains to be explained how centrally located hypoxic cells could physically become invasive. It is noteworthy that the number of viable cell layers within a tumor duct varies and that the hypoxic zone can be separated from the basal membrane by only one or two cell layers. Taking into account that tumor growth is a dynamic process, one might envisage a situation in which the hypoxic zone extends to the basal membrane and the hypoxic cells break down basal membrane proteins and become invasive as the result of an acquired aggressive phenotype. Thus, apart from the already known effects of hypoxia on tumor behavior, such as decreased vulnerability to cytotoxic drugs and ionizing radiation (7)
, increased metastatic potential (8)
, and increased mutation frequency (9)
, the data presented here support dedifferentiation as an additional consequence of hypoxia and a novel mechanism for tumor progression in hypoxic breast cancer lesions (Fig. 4)
.
|
| FOOTNOTES |
|---|
1 This work was supported by The Swedish Cancer Society, the Childrens Cancer Foundation of Sweden, HKH Kronprinsessan Lovisas Förening för Barnasjukvård, Hans von Kantzows Stiftelse, and by Malmö University Hospital research funds. ![]()
2 To whom requests for reprints should be addressed, at Lund University, Department of Laboratory Medicine, Entrance 78, 3rd Floor, University Hospital MAS, S-205 02 Malmö, Sweden. Phone: 46-40337403; Fax: 46-40337322; E-mail: sven.pahlman{at}molmed.mas.lu.se ![]()
3 The abbreviations used are: HIF, hypoxia inducible factor; DCIS, ductal carcinoma in situ; ER, estrogen receptor; CK, cytokeratin; TUNEL, terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling; N/C, nuclear/cytoplasm. ![]()
4 Å. Kronblad, K. Helczynska, M. Lodén, N. H. Nielsen, S. Emdin, S. Påhlman, and G. Landberg. "Regional cyclin D1 overexpression or hypoxia provides an explanation for downregulated, heterogeneous estrogen receptor-
expression in human breast cancer," submitted for publication. ![]()
Received 9/23/02. Accepted 2/18/03.
| REFERENCES |
|---|
|
|
|---|
regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA, 94: 4273-4278, 1997.
during breast carcinogenesis. J. Natl. Cancer Inst. (Bethesda), 93: 309-314, 2001.
in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (Lond.), 394: 485-490, 1998.[Medline]This article has been cited by other articles:
![]() |
A.-M. Larsson, K. Jirstrom, E. Fredlund, S. Nilsson, L. Ryden, G. Landberg, and S. Pahlman Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer Clin. Cancer Res., September 1, 2009; 15(17): 5552 - 5559. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Perot, J. Derre, J.-M. Coindre, F. Tirode, C. Lucchesi, O. Mariani, L. Gibault, L. Guillou, P. Terrier, and A. Aurias Strong Smooth Muscle Differentiation Is Dependent on Myocardin Gene Amplification in Most Human Retroperitoneal Leiomyosarcomas Cancer Res., March 15, 2009; 69(6): 2269 - 2278. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Helczynska, A.-M. Larsson, L. Holmquist Mengelbier, E. Bridges, E. Fredlund, S. Borgquist, G. Landberg, S. Pahlman, and K. Jirstrom Hypoxia-Inducible Factor-2{alpha} Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer Cancer Res., November 15, 2008; 68(22): 9212 - 9220. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ao, H. Wang, S. Kamarajugadda, and J. Lu Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors PNAS, June 3, 2008; 105(22): 7821 - 7826. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Seifeddine, A. Dreiem, E. Blanc, M.-C. Fulchignoni-Lataud, M.-A. L. F. Belda, F. Lecuru, T. H. Mayi, N. Mazure, V. Favaudon, C. Massaad, et al. Hypoxia Down-regulates CCAAT/Enhancer Binding Protein-{alpha} Expression in Breast Cancer Cells Cancer Res., April 1, 2008; 68(7): 2158 - 2165. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dubsky, P. Sevelda, R. Jakesz, H. Hausmaninger, H. Samonigg, M. Seifert, U. Denison, B. Mlineritsch, G. Steger, W. Kwasny, et al. Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy Clin. Cancer Res., April 1, 2008; 14(7): 2082 - 2087. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hoogewijs, N. B. Terwilliger, K. A. Webster, J. A. Powell-Coffman, S. Tokishita, H. Yamagata, T. Hankeln, T. Burmester, K. T. Rytkonen, M. Nikinmaa, et al. From critters to cancers: bridging comparative and clinical research on oxygen sensing, HIF signaling, and adaptations towards hypoxia Integr. Comp. Biol., October 1, 2007; 47(4): 552 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Brennan, K. Jirstrom, A. Kronblad, R. C. Millikan, G. Landberg, M. J. Duffy, L. Ryden, W. M. Gallagher, and S. L. O'Brien CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clin. Cancer Res., November 1, 2006; 12(21): 6421 - 6431. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Lin, Y.-J. Lee, and Z. Yun Differentiation Arrest by Hypoxia J. Biol. Chem., October 13, 2006; 281(41): 30678 - 30683. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Garofalo, M. Koda, S. Cascio, M. Sulkowska, L. Kanczuga-Koda, J. Golaszewska, A. Russo, S. Sulkowski, and E. Surmacz Increased Expression of Leptin and the Leptin Receptor as a Marker of Breast Cancer Progression: Possible Role of Obesity-Related Stimuli Clin. Cancer Res., March 1, 2006; 12(5): 1447 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Jokilehto, K. Rantanen, M. Luukkaa, P. Heikkinen, R. Grenman, H. Minn, P. Kronqvist, and P. M. Jaakkola Overexpression and Nuclear Translocation of Hypoxia-Inducible Factor Prolyl Hydroxylase PHD2 in Head and Neck Squamous Cell Carcinoma Is Associated with Tumor Aggressiveness Clin. Cancer Res., February 15, 2006; 12(4): 1080 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Calzada, M. A. Esteban, M. Feijoo-Cuaresma, M. C. Castellanos, S. Naranjo-Suarez, E. Temes, F. Mendez, M. Yanez-Mo, M. Ohh, and M. O. Landazuri von Hippel-Lindau Tumor Suppressor Protein Regulates the Assembly of Intercellular Junctions in Renal Cancer Cells through Hypoxia-Inducible Factor-Independent Mechanisms Cancer Res., February 1, 2006; 66(3): 1553 - 1560. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Hong, P. Kumar, L. Wang, B. Damania, M. L. Gulley, H.-J. Delecluse, P. J. Polverini, and S. C. Kenney Epstein-Barr Virus Lytic Infection Is Required for Efficient Production of the Angiogenesis Factor Vascular Endothelial Growth Factor in Lymphoblastoid Cell Lines J. Virol., November 15, 2005; 79(22): 13984 - 13992. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Karlsson, A. Edsjo, S. Pahlman, and H. M. Pettersson Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia Mol. Cancer Ther., July 1, 2005; 4(7): 1128 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cooper, G.-Y. Liu, Y.-L. Niu, S. Santos, L. C. Murphy, and P. H. Watson Intermittent Hypoxia Induces Proteasome-Dependent Down-Regulation of Estrogen Receptor {alpha} in Human Breast Carcinoma Clin. Cancer Res., December 15, 2004; 10(24): 8720 - 8727. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lofstedt, A. Jogi, M. Sigvardsson, K. Gradin, L. Poellinger, S. Pahlman, and H. Axelson Induction of ID2 Expression by Hypoxia-inducible Factor-1: A ROLE IN DEDIFFERENTIATION OF HYPOXIC NEUROBLASTOMA CELLS J. Biol. Chem., September 17, 2004; 279(38): 39223 - 39231. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Okami, D. M. Simeone, and C. D. Logsdon Silencing of the Hypoxia-Inducible Cell Death Protein BNIP3 in Pancreatic Cancer Cancer Res., August 1, 2004; 64(15): 5338 - 5346. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Streubel, A. Chott, D. Huber, M. Exner, U. Jager, O. Wagner, and I. Schwarzinger Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas N. Engl. J. Med., July 15, 2004; 351(3): 250 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Qi, S. Borowicz, R. Pramanik, R. M. Schultz, J. Han, and G. Chen Estrogen Receptor Inhibits c-Jun-dependent Stress-induced Cell Death by Binding and Modifying c-Jun Activity in Human Breast Cancer Cells J. Biol. Chem., February 20, 2004; 279(8): 6769 - 6777. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S Cherniack Oxygen sensing: applications in humans J Appl Physiol, January 1, 2004; 96(1): 352 - 358. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |